HomeBody MapPeptidesCalculator
Catalog11 refs

IGF-1 LR3

Healing & RecoveryMuscle & PerformancetherapeuticResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
4-6 weeks maximum; equal break recommended
Half-life
18
Uses
20
Typical
Body Map
Loading 3D model…
MusclesJointsSkin
Overview

IGF-1 LR3 (Long R3 IGF-1) is a modified form of insulin-like growth factor 1 with significantly enhanced potency and half-life compared to native IGF-1. The modifications — an arginine substitution at position 3 and a 13-amino-acid N-terminal extension — reduce binding to IGF binding proteins (IGFBPs) by approximately 100-fold, leaving dramatically more free IGF-1 available to activate IGF-1 receptors. With a half-life extended from minutes to approximately 20–30 hours, IGF-1 LR3 is one of the most potent anabolic peptides researched for muscle growth, cell proliferation, and tissue repair.

Primary Uses
Muscle growth / anabolic
Cell proliferation / recovery
Metabolic
muscle growth
cell proliferation
tissue repair
cell culture media supplement
Cell growth and hypertrophy models
Reduced IGFBP-binding studies
Muscle anabolism
Recovery protocols
Muscle hypertrophy
Anti-catabolism
Muscle hyperplasia
Wound healing
Ligament/tendon recovery
Nutrient partitioning
Fat loss
Protocol Reference
Dose
20–100mcg (start low
Frequency
Injection (subcutaneous)
Half-life
4-6 weeks maximum; equal break recommended
Route
escalate based on response)
Evidence
limited / Preclinical (disputed)
Research References· 5
Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency
PubMedPMID 1381175. Journal of Molecular Endocrinology, 1992.
Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection
PubMedPMID 8655878. Journal of Endocrinology, 1996.
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
PubMedPMID 15094271. The Lancet, 2004.
Research Models
MouseRatSheep
Also in Healing & Recovery
Healing & Recovery
ARA-290 (Cibinetide)
Nerve pain · Small fiber neuropathy
Healing & Recovery
BPC-157
Wound healing · Tendon repair
Healing & Recovery
Cartalax (AED peptide)
Joint and connective tissue support · Anti-aging effects on fibroblasts
Healing & Recovery
Chonluten (EDG)
Normalizes respiratory system function · Regulates protein synthesis in lung tissue
Compare